Biotechnology

Odyssey Therapeutics

TPG GP A Acquires Odyssey Therapeutics Shares at $18

SR One Capital Management Increases Holdings in Odyssey Therapeutics and Makes Open Market Trades

Jeffrey M. Leiden Buys Odyssey Therapeutics Shares and Increases Holding

Odyssey Therapeutics Director Lǐ Nán Buys $20 Million of Common Stock

Odyssey Therapeutics Director Shelley Chu Buys 11,111 Shares During IPO

Odyssey Therapeutics Conducts Unregistered Private Equity Sale

ODTX.US released FY2024 Annual Earnings on April 17, 2026 (BJT) with actual revenue of USD 4.472 M and EPS of USD -16.6295

ODTX.US released FY2025 Annual Earnings on April 17 (BJT), actual revenue USD 2.976 M, actual EPS USD -5.1589

HCW Biologics

P3 Health Partners

Murano Global BV

Auddia

Super League Enterprise

Trio-Tech Int

Ernexa Therapeutics

Robostrategy

Jiade

ODTX

<p>Jeito II S.L.P., a French investment fund, has acquired a 7.8% stake in Odyssey Therapeutics, Inc., purchasing 1,388,888 shares at $18 during the company's IPO. This investment allows Jeito to exert significant influence, with an executive already on Odyssey's board. Jeito plans to review its position and may adjust its holdings while maintaining an active dialogue with Odyssey's management.</p>

TradingView

Jeito II S.L.P. Discloses Investment in Odyssey Therapeutics with 7.8% Stake

Odyssey Therapeutics(ODTX.US)

Jeito II S.L.P. Discloses Investment in Odyssey Therapeutics with 7.8% Stake